Invega sustenna and Attention deficit hyperactivity disorder - a phase IV clinical study of FDA data

Summary:

Attention deficit hyperactivity disorder is reported as a side effect among people who take Invega sustenna (paliperidone palmitate), especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months also take Metformin, and have Bipolar disorder.

The phase IV clinical study analyzes which people have Attention deficit hyperactivity disorder when taking Invega sustenna. It is created by eHealthMe based on reports of 23,130 people who have side effects when taking Invega sustenna from the FDA, and is updated regularly.

What is Invega sustenna?

Invega sustenna has active ingredients of paliperidone palmitate. It is often used in schizophrenia. eHealthMe is studying from 23,232 Invega sustenna users. Check the latest studies of Invega sustenna.

What is Attention deficit hyperactivity disorder?

Attention deficit hyperactivity disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness) is found to be associated with 609 drugs and 1,393 conditions by eHealthMe. Check the latest studies of Attention deficit hyperactivity disorder.

On Jul, 17, 2026

23,130 people reported to have side effects when taking Invega sustenna.
Among them, 13 people (0.06%) have Attention deficit hyperactivity disorder.

Could Invega sustenna cause Attention deficit hyperactivity disorder?

Among these 13 people:

How long have people been on Invega sustenna when they have Attention deficit hyperactivity disorder? *

What is the gender of people who have Attention deficit hyperactivity disorder when taking Invega sustenna? *

female: 23.08 %
male: 76.92 %

What is the age of people who have Attention deficit hyperactivity disorder when taking Invega sustenna? *

What are other drugs people take besides Invega sustenna? *

What are other side effects people have besides Attention deficit hyperactivity disorder? *

Depression: 3 people, 23.08%
Drug Ineffective: 2 people, 15.38%
Stress And Anxiety: 2 people, 15.38%
Mania (a state of abnormally elevated or irritable mood): 2 people, 15.38%
Road Traffic Accident: 2 people, 15.38%
Weight Loss: 1 person, 7.69%
Heart Palpitations (feelings or sensations that your heart is pounding or racing): 1 person, 7.69%
Gynecomastia (enlargement of the gland tissue of the male breast): 1 person, 7.69%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 1 person, 7.69%
Fatigue (feeling of tiredness): 1 person, 7.69%

What are the existing conditions these people have? *

Bipolar Disorder (mood disorder): 3 people, 23.08%
Type 2 Diabetes: 2 people, 15.38%
Sinus Disorder (disease of sinus): 2 people, 15.38%
Stress And Anxiety: 1 person, 7.69%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 7.69%
Drowsiness: 1 person, 7.69%
Constipation: 1 person, 7.69%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 1 person, 7.69%
Affective Disorder (mental disorder): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Invega sustenna and have Attention deficit hyperactivity disorder?

- Check whether Attention deficit hyperactivity disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Invega sustenna:

Invega sustenna (23,232 reports)

Attention deficit hyperactivity disorder treatments and more:

Attention deficit hyperactivity disorder (120,336 reports)

How severe was Attention deficit hyperactivity disorder and when was it recovered:

Attention deficit hyperactivity disorder in Invega sustenna

Expand to all the drugs that have ingredients of paliperidone palmitate:

Attention deficit hyperactivity disorder and drugs with ingredients of paliperidone palmitate (14 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Invega sustenna:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Attention deficit hyperactivity disorder:

Attention deficit hyperactivity disorder (609 drugs)

Browse all the conditions that are associated with Attention deficit hyperactivity disorder:

Attention deficit hyperactivity disorder (1,393 conditions)

Related publications that referenced our studies

Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .
Lufi D, Bucherman M, Akita M, Cohen R, Sibani C, "The effect of methylphenidate on speech patterns of children with attention deficit disorder", Journal of Behavioral Health, 2012 Jan .
Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .
Lufi D, Bucherman M, Akita M, Cohen R, Sibani C, "The effect of methylphenidate on speech patterns of children with attention deficit disorder", Journal of Behavioral Health, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on paliperidone palmitate (the active ingredients of Invega sustenna) and Invega sustenna (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.